Can a 30-minute bike ride help fight liver cancer? scientists investigate.
NCT ID NCT07189624
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study will look at how a single 30-minute bike ride changes levels of certain liver proteins (FGF21 and follistatin) in 12 people with liver cancer. Researchers want to understand how exercise affects the body in these patients, which could lead to better exercise recommendations. The study does not test any drug or treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors design safe and effective exercise programs for people with liver cancer.
- What could go wrong
- This is a very small, early study (12 people) that only looks at short-term changes after one exercise session. It won't test whether exercise improves health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 12 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Apr 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Hepatocellular carcinoma developed on cirrhosis * Cirrhosis of any etiology, defined by a liver elasticity measurement \>15kPa or a history of cirrhosis decompensation * Hepatocellular carcinoma with indication for treatment by immunotherapy or chemoembolization * Child-Pugh scores A and B7 * WHO score ≤ 2 * Affiliation to french national social security system Exclusion Criteria: * Hepatic encephalopathy grade II or higher * Bone metastasis * Surgery performed within 30 days prior to inclusion visit * Liver transplant * Muscle injury within 3 months of inclusion * Pregnant or breast-feeding women * Patients under legal protection (guardianship, curatorship, safeguard of justice) * Participation in another clinical trial within 10 days of inclusion
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cirrhosis with hepatocellular carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Clermont-Ferrand
Clermont-Ferrand, France
-
Chu Estaing Medecine Digestive Et Hepatobiliaire
Clermont-Ferrand, 63003, France